Oncogenic BRAF is a critical driver of proliferation and survival and is thus a validated therapeutic target in cancer. We have developed a potent inhibitor, termed 1t (CCT239065), of the mutant protein kinase, V600EBRAF. 1t inhibits signaling downstream of V600EBRAF in cancer cells, blocking DNA synthesis, and inhibiting proliferation. Importantly, we show that 1t is considerably more selective for mutated BRAF cancer cell lines compared with wild-type BRAF lines. The inhibitor is well tolerated in mice and exhibits excellent oral bioavailability (F = 71%). Suppression of V600EBRAF-mediated signaling in human tumor xenografts was observed following oral administration of a single dose of 1t. As expected, the growth rate in vivo of a wild-type BRAF human tumor xenograft model is unaffected by inhibitor 1t. In contrast, 1t elicits significant therapeutic responses in mutant BRAF-driven human melanoma xenografts. ©2010 AACR.

A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF / Whittaker, Steven; Ménard, Delphine; Kirk, Ruth; Ogilvie, Lesley; Hedley, Douglas; Zambon, Alfonso; Lopes, Filipa; Preece, Natasha; Manne, Helen; Rana, Sareena; Lambros, Maryou; Reis Filho, Jorge S.; Marais, Richard; Springer, Caroline J.. - In: CANCER RESEARCH. - ISSN 0008-5472. - 70:20(2010), pp. 8036-8044. [10.1158/0008-5472.CAN-10-1366]

A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF

ZAMBON, Alfonso;
2010

Abstract

Oncogenic BRAF is a critical driver of proliferation and survival and is thus a validated therapeutic target in cancer. We have developed a potent inhibitor, termed 1t (CCT239065), of the mutant protein kinase, V600EBRAF. 1t inhibits signaling downstream of V600EBRAF in cancer cells, blocking DNA synthesis, and inhibiting proliferation. Importantly, we show that 1t is considerably more selective for mutated BRAF cancer cell lines compared with wild-type BRAF lines. The inhibitor is well tolerated in mice and exhibits excellent oral bioavailability (F = 71%). Suppression of V600EBRAF-mediated signaling in human tumor xenografts was observed following oral administration of a single dose of 1t. As expected, the growth rate in vivo of a wild-type BRAF human tumor xenograft model is unaffected by inhibitor 1t. In contrast, 1t elicits significant therapeutic responses in mutant BRAF-driven human melanoma xenografts. ©2010 AACR.
2010
70
20
8036
8044
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF / Whittaker, Steven; Ménard, Delphine; Kirk, Ruth; Ogilvie, Lesley; Hedley, Douglas; Zambon, Alfonso; Lopes, Filipa; Preece, Natasha; Manne, Helen; Rana, Sareena; Lambros, Maryou; Reis Filho, Jorge S.; Marais, Richard; Springer, Caroline J.. - In: CANCER RESEARCH. - ISSN 0008-5472. - 70:20(2010), pp. 8036-8044. [10.1158/0008-5472.CAN-10-1366]
Whittaker, Steven; Ménard, Delphine; Kirk, Ruth; Ogilvie, Lesley; Hedley, Douglas; Zambon, Alfonso; Lopes, Filipa; Preece, Natasha; Manne, Helen; Rana...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1138843
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 14
social impact